Hologic Could See $27.9M in Additional Annual Revenue, Piper Jaffray Says

Shares of Hologic, Inc

have moved higher 1.7 percent to $21.38 in Monday's trading following some bullish comments from Piper Jaffray. Analyst William Quirk believes Hologic could see ~$27.9 million in annual revenue from Grifols' seven year contract with the Japanese Green Cross to screen blood supply using Procleix. The deal between Grifols and the Japanese Green Cross is valued at $375 million, meaning $195 million in revenue for Hologic at the current revenue split agreement. Quirk maintained a Neutral rating on the stock.